65 and older, any sex, with Hip Fractures. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Evaluation of the Analgesic Efficacy of Both Local Anesthetics in the Regional Block of Hip Fracture SurgeryPrimary· 6h, 12h, 24h and 48h
The primary measure of efficacy in this study will be the difference in block duration. To evaluate this, the need for rescue medication will be assessed at several time points, including 6, 12, 24, and 48 hours.
6h
Group
Value
95% CI
LEVOBUPIVACAINE
10
ROPIVACAINE
4
12h
Group
Value
95% CI
LEVOBUPIVACAINE
12
ROPIVACAINE
14
24h
Group
Value
95% CI
LEVOBUPIVACAINE
21
ROPIVACAINE
17
48h
Group
Value
95% CI
LEVOBUPIVACAINE
10
ROPIVACAINE
14
No rescue
Group
Value
95% CI
LEVOBUPIVACAINE
3
ROPIVACAINE
3
Latency of Initiation.Secondary· The duration of treatment for each patient will be considered until the evaluation of the analgesic scale corresponding to 48 hours after the procedure is performed.
This study aims to describe the behavior of the combined technique in hip fractures by establishing the latency of initiation.
Latency: evaluated by analgesic scales up to 48 hours. Analgesic scales: EVN - numerical verbal scale- (0= No pain (min) - 10=The worst pain imaginable (max)), Algoplus (0=min - 5=max) and PAINAD -Paint Assessment in Advanced Dementia- (0=min - 10=Max). They will be carried out at 6, 12, 24 and 48 h after the procedure blocking. In both scales, the lowest values are those of better outcome and the highest are those of worst outcome.
Need and rescue drugs: rescue anal
6h
Group
Value
95% CI
EVN Scale - LEVOBUPIVACAINE
1.92
± 1.04
EVN - Scale ROPIVACAINE
1.68
± 2.56
ALGOPLUS Scale - LEVOBUPIVACAINE
0.94
± 1.25
ALGOPLUS Scale - ROPIVACAINE
0.75
± 1.04
PAINAD Scale - LEVOBUPIVACAINE
1.46
± 2.05
PAINAD Scale - ROPIVACAINE
1.04
± 1.67
12h
Group
Value
95% CI
EVN Scale - LEVOBUPIVACAINE
2.50
± 2.26
EVN - Scale ROPIVACAINE
2.91
± 3.15
ALGOPLUS Scale - LEVOBUPIVACAINE
1.3
± 1.06
ALGOPLUS Scale - ROPIVACAINE
1.38
± 1.43
PAINAD Scale - LEVOBUPIVACAINE
1.95
± 1.69
PAINAD Scale - ROPIVACAINE
1.84
± 1.99
24h
Group
Value
95% CI
EVN Scale - LEVOBUPIVACAINE
4.33
± 2.79
EVN - Scale ROPIVACAINE
3.5
± 2.82
ALGOPLUS Scale - LEVOBUPIVACAINE
2.16
± 1.37
ALGOPLUS Scale - ROPIVACAINE
1.70
± 1.28
PAINAD Scale - LEVOBUPIVACAINE
3.22
± 1.99
PAINAD Scale - ROPIVACAINE
2.76
± 2.17
48h
Group
Value
95% CI
EVN Scale - LEVOBUPIVACAINE
4.72
± 2.66
EVN - Scale ROPIVACAINE
4.58
± 2.84
ALGOPLUS Scale - LEVOBUPIVACAINE
2.32
± 1.27
ALGOPLUS Scale - ROPIVACAINE
2.21
± 1.33
PAINAD Scale - LEVOBUPIVACAINE
3.75
± 2.33
PAINAD Scale - ROPIVACAINE
3.36
± 2.14
Sponsor's own description
Prospective, low-level, non-commercial intervention, comparative clinical trial (phase IV) of balanced, randomized groups, to compare the analgesic efficacy of the local anesthetics Ropivacaine and Levobupivacaine in peripheral nerve block in hip fracture surgery in the elderly .
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06695468 — Efficacy and Safety of Adding Dexmedetomidine to Levobupivacaine in Rectus Sheath Block Compared to Quadratus Lumborum B
· Phase 4
· not yet recruiting
NCT06410404 — Dexmeditomedine as an Adjuvant to Levobupivacaine in Transversus Thoracis Plane Block on the Management of Post-sternoto
· NA
· not yet recruiting
NCT06011746 — Adding Ketamine to Levobupivacaine in Paravertebral Block in Thoracotomy
· Phase 4
· completed
NCT05877131 — Evaluate Efficacy Levobupivacaine 0.125% Versuss Ropivacaine 0.2% in Hemodynamic Alterations in Labor and Fetal Repercus
· Phase 4
· unknown
NCT05600296 — Ultrasound-guided Ilioinguinal/Iliohypogastric Nerve Block Compared to the Combined Therapy With Spermatic Cord Block
· Phase 1
· completed
Other recruiting trials for Hip Fractures
Currently open trials in the same condition.
NCT07239817 — PENG Block + LIA For Endoprosthesis Surgery With Anterior Approach
· NA
· recruiting
NCT07002723 — Effects of Esketamine Combined With Dexmedetomidine on Postoperative Sleep Quality
· NA
· recruiting
NCT06893406 — Cervical Myelopathy in Hip Fracture Patients
· NA
· recruiting
NCT06565910 — Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG)
· Phase 4
· recruiting
NCT06455813 — What Laxative Should be Used After Hip Fracture Surgery?
· Phase 4
· recruiting
Other Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León trials
Trials by the same sponsor.
NCT05419947 — Clinical Trial for the Optimization of Indocyanine Green Administration in NIRF-C During L.Cholecystectomy.
· Phase 4
· completed
NCT05435157 — Residual Gastric Volume Measured by Ultrasound in Diabetic Surgical Population Versus Non-diabetic Surgical Population.
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Last refreshed: 19 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04773301.